Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

NCT06171282 is registered in ClinicalTrials.gov with Shanghai Yunying Medical Technology as lead sponsor.

NCT NCT06171282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06171282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
Lead sponsor
Shanghai Yunying Medical Technology
Phase
Phase 1
Overall status
Unknown status
Start date
July 12, 2023
Completion date
July 12, 2026
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone tumor, osteosarcoma, sarcoma, soft tissue sarcoma